$PBIO Pressure BioSciences to Expand on Pivotal Ch
Post# of 1354
(Total Views: 191)
Posted On: 09/13/2022 10:16:55 AM
$PBIO Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th
https://www.accesswire.com/715767/pressure-bi...ember-13th
Company Shifts Primary Business Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with
Ten or More Tolling Contracts. Believes Each Contract Could Generate $1 Million or More in PBI Revenue.
SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company"
, a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the September 12-14 H. C. Wainwright Annual Global Investor Conference. This conference will feature a number of exciting, rapidly-growing public and private companies, presenting for 30 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking on September 13th at 1:30 pm ET.
Over the past four months, PBI has announced the execution of three agreements covering the production, distribution, commercial roll-out, and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use. Recently, the Company also announced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with over $500 million in QVC sales.
All four contracts are based on the use of the Company's patented, Ultra Shear Technology™ (UST™) platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The Company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The Company plans to close on a minimum of six additional contracts over the remaining months of FY 2022.
DATE: Tuesday, September 13, 2022 (1:30 pm ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Link to PBIO Presentation - HCW Investor Conf.
Highlights of PBI's Recent Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Products - with Estimated Annual 2023 Revenue to PBI Expected to Exceed $5,000,000:
PBI has executed three contracts that call for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk material during Q4 2022
CBD bulk nanoemulsion material will be sent to the Company's contractors who will vial, label, sell, and distribute the material via their e-commerce sites, sub-distributors, and other established sales channels
These unique products are expected to be long-term stable, effectively water-soluble, highly bioavailable nanoemulsions of CBD for oral and topical use
Formulation of the initial products has been completed: only plant-based reagents are used in the products
Safer Medical of Montana (SMM), Canopy CBD Farms (CCF), and North Star Holdings (NSH) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of these partnerships are in agreements that were recently executed by the companies and PBI
These companies have distribution channels and infrastructure for their current health & wellness products
PBI believes first-year sales (FY 2023) will meet or exceed $5M in revenue for PBI
PBI believes no other CBD product on the market can compete with the quality of its UST-processed Nano-CBD
PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to enhance existing skincare products sold under the Dr. Denese label. UST-processed products are expected for FY 2023 release.
https://www.accesswire.com/715767/pressure-bi...ember-13th
Company Shifts Primary Business Focus to Revolutionary UST Platform. Expects to Enter FY 2023 with
Ten or More Tolling Contracts. Believes Each Contract Could Generate $1 Million or More in PBI Revenue.
SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company" , a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food & beverage, and other key industries, today announced the Company's participation in the September 12-14 H. C. Wainwright Annual Global Investor Conference. This conference will feature a number of exciting, rapidly-growing public and private companies, presenting for 30 minutes each. PBI's President and CEO, Mr. Richard T. Schumacher, will be speaking on September 13th at 1:30 pm ET. Over the past four months, PBI has announced the execution of three agreements covering the production, distribution, commercial roll-out, and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use. Recently, the Company also announced the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with over $500 million in QVC sales.
All four contracts are based on the use of the Company's patented, Ultra Shear Technology™ (UST™) platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The Company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The Company plans to close on a minimum of six additional contracts over the remaining months of FY 2022.
DATE: Tuesday, September 13, 2022 (1:30 pm ET)
PRESENTATION: Video Webcast - Presentation plus Q&A
REGISTER: Link to PBIO Presentation - HCW Investor Conf.
Highlights of PBI's Recent Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Products - with Estimated Annual 2023 Revenue to PBI Expected to Exceed $5,000,000:
PBI has executed three contracts that call for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk material during Q4 2022
CBD bulk nanoemulsion material will be sent to the Company's contractors who will vial, label, sell, and distribute the material via their e-commerce sites, sub-distributors, and other established sales channels
These unique products are expected to be long-term stable, effectively water-soluble, highly bioavailable nanoemulsions of CBD for oral and topical use
Formulation of the initial products has been completed: only plant-based reagents are used in the products
Safer Medical of Montana (SMM), Canopy CBD Farms (CCF), and North Star Holdings (NSH) will partner with PBI on production, distribution, commercial roll-out, and financial returns - terms of these partnerships are in agreements that were recently executed by the companies and PBI
These companies have distribution channels and infrastructure for their current health & wellness products
PBI believes first-year sales (FY 2023) will meet or exceed $5M in revenue for PBI
PBI believes no other CBD product on the market can compete with the quality of its UST-processed Nano-CBD
PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to enhance existing skincare products sold under the Dr. Denese label. UST-processed products are expected for FY 2023 release.
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼